| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cancer Vaccines | 32 | 2018 | 759 | 3.770 |
Why?
|
| Melanoma, Experimental | 25 | 2022 | 382 | 2.700 |
Why?
|
| CD8-Positive T-Lymphocytes | 32 | 2022 | 1656 | 2.470 |
Why?
|
| Immunotherapy | 23 | 2024 | 3561 | 1.710 |
Why?
|
| Melanoma | 29 | 2022 | 5601 | 1.610 |
Why?
|
| Interleukin-2 | 13 | 2024 | 889 | 1.520 |
Why?
|
| T-Lymphocytes | 21 | 2023 | 3946 | 1.170 |
Why?
|
| gp100 Melanoma Antigen | 11 | 2018 | 94 | 0.970 |
Why?
|
| Immune Tolerance | 8 | 2017 | 434 | 0.950 |
Why?
|
| Peptides | 6 | 2019 | 1502 | 0.920 |
Why?
|
| T-Lymphocytes, Regulatory | 10 | 2024 | 705 | 0.890 |
Why?
|
| Immune System | 2 | 2017 | 275 | 0.890 |
Why?
|
| CTLA-4 Antigen | 9 | 2024 | 679 | 0.870 |
Why?
|
| Autoimmunity | 3 | 2020 | 264 | 0.860 |
Why?
|
| Immunotherapy, Active | 3 | 2015 | 48 | 0.820 |
Why?
|
| Tumor Microenvironment | 13 | 2023 | 3054 | 0.780 |
Why?
|
| Antigens, Neoplasm | 19 | 2017 | 1581 | 0.770 |
Why?
|
| Antigen Presentation | 6 | 2018 | 286 | 0.730 |
Why?
|
| Bioengineering | 1 | 2020 | 23 | 0.720 |
Why?
|
| Mice | 76 | 2024 | 35421 | 0.720 |
Why?
|
| Neoplasms | 20 | 2021 | 15952 | 0.690 |
Why?
|
| Dendritic Cells | 16 | 2018 | 1104 | 0.690 |
Why?
|
| CD40 Antigens | 3 | 2017 | 107 | 0.690 |
Why?
|
| Neoplasms, Experimental | 6 | 2018 | 784 | 0.670 |
Why?
|
| Animals | 85 | 2024 | 61363 | 0.650 |
Why?
|
| T-Lymphocytes, Cytotoxic | 11 | 2020 | 1019 | 0.650 |
Why?
|
| Mice, Inbred C57BL | 38 | 2024 | 7054 | 0.640 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2020 | 383 | 0.620 |
Why?
|
| Lymphocyte Activation | 17 | 2020 | 1719 | 0.600 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 11 | 2022 | 1033 | 0.590 |
Why?
|
| Interleukins | 4 | 2017 | 340 | 0.590 |
Why?
|
| Interferon-alpha | 6 | 2016 | 958 | 0.580 |
Why?
|
| CD40 Ligand | 2 | 2017 | 130 | 0.580 |
Why?
|
| Myeloid Cells | 4 | 2014 | 274 | 0.560 |
Why?
|
| Cytotoxicity, Immunologic | 11 | 2019 | 691 | 0.560 |
Why?
|
| CD4-Positive T-Lymphocytes | 7 | 2015 | 1044 | 0.550 |
Why?
|
| Adoptive Transfer | 7 | 2012 | 431 | 0.550 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2018 | 271 | 0.540 |
Why?
|
| Toll-Like Receptor 7 | 2 | 2022 | 30 | 0.530 |
Why?
|
| T-Lymphocyte Subsets | 5 | 2016 | 587 | 0.510 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2018 | 224 | 0.510 |
Why?
|
| Membrane Glycoproteins | 8 | 2008 | 1091 | 0.510 |
Why?
|
| Interleukin-15 | 5 | 2023 | 197 | 0.500 |
Why?
|
| Immunotherapy, Adoptive | 9 | 2019 | 1860 | 0.490 |
Why?
|
| Cell Line, Tumor | 27 | 2024 | 14886 | 0.480 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2014 | 21 | 0.480 |
Why?
|
| Cyclooxygenase 2 | 1 | 2017 | 496 | 0.480 |
Why?
|
| Wilms Tumor | 1 | 2017 | 302 | 0.460 |
Why?
|
| Adjuvants, Immunologic | 5 | 2018 | 669 | 0.460 |
Why?
|
| Interferon-gamma | 11 | 2020 | 1169 | 0.450 |
Why?
|
| Adaptive Immunity | 1 | 2014 | 151 | 0.430 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2012 | 262 | 0.420 |
Why?
|
| Antibodies, Monoclonal | 5 | 2017 | 4470 | 0.420 |
Why?
|
| Polyethylene Glycols | 3 | 2021 | 654 | 0.410 |
Why?
|
| Tumor Escape | 6 | 2017 | 247 | 0.400 |
Why?
|
| Programmed Cell Death 1 Receptor | 7 | 2022 | 1096 | 0.390 |
Why?
|
| B7-H1 Antigen | 2 | 2018 | 1098 | 0.390 |
Why?
|
| Neoplasm Metastasis | 6 | 2021 | 5332 | 0.360 |
Why?
|
| Immunity, Innate | 2 | 2014 | 697 | 0.360 |
Why?
|
| Neoplasm Proteins | 8 | 2017 | 3345 | 0.340 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2021 | 5417 | 0.320 |
Why?
|
| Vaccines, Subunit | 3 | 2018 | 125 | 0.320 |
Why?
|
| Killer Cells, Natural | 7 | 2023 | 967 | 0.310 |
Why?
|
| Disease Models, Animal | 12 | 2020 | 7323 | 0.300 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 2454 | 0.300 |
Why?
|
| Lysine | 1 | 2010 | 426 | 0.300 |
Why?
|
| Mice, Knockout | 13 | 2017 | 5692 | 0.290 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2019 | 225 | 0.290 |
Why?
|
| Vaccinia virus | 10 | 2002 | 78 | 0.270 |
Why?
|
| Antineoplastic Agents | 10 | 2023 | 14639 | 0.260 |
Why?
|
| Receptors, Antigen, T-Cell | 5 | 2023 | 1136 | 0.260 |
Why?
|
| Chemokine CCL2 | 2 | 2018 | 193 | 0.250 |
Why?
|
| Vitiligo | 3 | 2000 | 17 | 0.250 |
Why?
|
| Antibodies | 4 | 2022 | 802 | 0.250 |
Why?
|
| Melanocytes | 4 | 2001 | 240 | 0.250 |
Why?
|
| Humans | 65 | 2023 | 270809 | 0.240 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2020 | 3930 | 0.240 |
Why?
|
| Homeostasis | 2 | 2009 | 925 | 0.240 |
Why?
|
| Oligodeoxyribonucleotides | 3 | 2017 | 290 | 0.240 |
Why?
|
| Signal Transduction | 5 | 2021 | 12036 | 0.230 |
Why?
|
| beta-Galactosidase | 7 | 2002 | 272 | 0.230 |
Why?
|
| Immunologic Memory | 4 | 2024 | 376 | 0.230 |
Why?
|
| Brain Neoplasms | 3 | 2017 | 4971 | 0.220 |
Why?
|
| Mice, Transgenic | 10 | 2018 | 4198 | 0.220 |
Why?
|
| Cytokines | 8 | 2021 | 2804 | 0.210 |
Why?
|
| Fas Ligand Protein | 2 | 2014 | 153 | 0.210 |
Why?
|
| Enzyme Inhibitors | 2 | 2010 | 1944 | 0.210 |
Why?
|
| Cell Proliferation | 12 | 2020 | 7233 | 0.210 |
Why?
|
| Cisplatin | 1 | 2010 | 2509 | 0.210 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2022 | 72 | 0.200 |
Why?
|
| Vaccines, Synthetic | 7 | 2001 | 325 | 0.190 |
Why?
|
| Cells, Cultured | 8 | 2015 | 5658 | 0.180 |
Why?
|
| Interleukin-1alpha | 1 | 2021 | 53 | 0.180 |
Why?
|
| Aurora Kinase B | 1 | 2020 | 67 | 0.180 |
Why?
|
| Phenotype | 5 | 2017 | 6503 | 0.180 |
Why?
|
| Interleukin-7 | 3 | 2013 | 92 | 0.180 |
Why?
|
| Proteins | 2 | 1999 | 2030 | 0.180 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 2 | 2017 | 19 | 0.180 |
Why?
|
| Antigens | 3 | 2009 | 279 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 153 | 0.170 |
Why?
|
| Cluster Analysis | 3 | 2017 | 1076 | 0.170 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2001 | 425 | 0.170 |
Why?
|
| Aurora Kinase A | 1 | 2020 | 209 | 0.160 |
Why?
|
| Self Tolerance | 3 | 2005 | 18 | 0.160 |
Why?
|
| Tumor Burden | 5 | 2020 | 2033 | 0.160 |
Why?
|
| Interferon Type I | 2 | 2016 | 282 | 0.160 |
Why?
|
| Vaccination | 3 | 2018 | 1113 | 0.160 |
Why?
|
| Ipilimumab | 2 | 2021 | 772 | 0.160 |
Why?
|
| Veratrum Alkaloids | 1 | 2018 | 35 | 0.160 |
Why?
|
| Histocompatibility Antigens Class I | 7 | 2016 | 246 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 10 | 2024 | 2419 | 0.160 |
Why?
|
| Female | 37 | 2024 | 148940 | 0.150 |
Why?
|
| Skin Neoplasms | 4 | 2021 | 4900 | 0.150 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2021 | 1336 | 0.150 |
Why?
|
| Oxidoreductases | 1 | 1999 | 168 | 0.150 |
Why?
|
| Prodrugs | 1 | 2020 | 226 | 0.150 |
Why?
|
| Receptors, CXCR3 | 1 | 2018 | 34 | 0.150 |
Why?
|
| Injections, Intralesional | 2 | 2017 | 170 | 0.150 |
Why?
|
| CD4-CD8 Ratio | 1 | 2017 | 57 | 0.150 |
Why?
|
| Macrophages | 2 | 2017 | 1334 | 0.150 |
Why?
|
| Autoantigens | 1 | 1999 | 247 | 0.150 |
Why?
|
| Imidazoles | 2 | 2014 | 1065 | 0.150 |
Why?
|
| Biomarkers | 4 | 2019 | 5050 | 0.140 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2018 | 215 | 0.140 |
Why?
|
| Apoptosis | 6 | 2020 | 7757 | 0.140 |
Why?
|
| Models, Biological | 3 | 2017 | 3187 | 0.140 |
Why?
|
| Immunity, Cellular | 2 | 2017 | 436 | 0.140 |
Why?
|
| B7 Antigens | 1 | 2017 | 85 | 0.140 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2017 | 111 | 0.140 |
Why?
|
| Tyrosine | 1 | 2018 | 503 | 0.140 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2016 | 78 | 0.130 |
Why?
|
| WT1 Proteins | 1 | 2017 | 107 | 0.130 |
Why?
|
| Inflammasomes | 1 | 2018 | 172 | 0.130 |
Why?
|
| Drug Synergism | 4 | 2015 | 1355 | 0.130 |
Why?
|
| Mutation | 7 | 2017 | 15922 | 0.130 |
Why?
|
| Interleukin-12 | 3 | 2024 | 266 | 0.130 |
Why?
|
| Receptors, Immunologic | 1 | 2017 | 310 | 0.130 |
Why?
|
| Genetic Vectors | 7 | 2015 | 1837 | 0.130 |
Why?
|
| Glioma | 2 | 2017 | 1986 | 0.130 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2017 | 361 | 0.120 |
Why?
|
| Glioblastoma | 2 | 2017 | 1781 | 0.120 |
Why?
|
| DNA Mismatch Repair | 1 | 2017 | 289 | 0.120 |
Why?
|
| Oligopeptides | 1 | 1997 | 450 | 0.120 |
Why?
|
| Stromal Cells | 1 | 2018 | 823 | 0.120 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 395 | 0.120 |
Why?
|
| Lymphoma | 2 | 2017 | 1516 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2016 | 253 | 0.120 |
Why?
|
| Chemokines | 2 | 2012 | 285 | 0.120 |
Why?
|
| Fibrin | 1 | 2014 | 82 | 0.120 |
Why?
|
| RNA-Induced Silencing Complex | 1 | 2014 | 26 | 0.120 |
Why?
|
| Receptor, Interferon alpha-beta | 2 | 2015 | 23 | 0.120 |
Why?
|
| Enzyme Activation | 1 | 2017 | 1801 | 0.110 |
Why?
|
| Paclitaxel | 2 | 2018 | 2114 | 0.110 |
Why?
|
| Monocytes | 1 | 2018 | 784 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2021 | 1858 | 0.110 |
Why?
|
| Polymers | 3 | 2023 | 223 | 0.110 |
Why?
|
| Coculture Techniques | 3 | 2012 | 626 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 3 | 2018 | 5264 | 0.110 |
Why?
|
| Vaccines, DNA | 2 | 2007 | 109 | 0.110 |
Why?
|
| Fibrinogen | 1 | 2014 | 211 | 0.110 |
Why?
|
| Receptors, Lipoxin | 1 | 2013 | 5 | 0.110 |
Why?
|
| Oncolytic Viruses | 1 | 2015 | 169 | 0.110 |
Why?
|
| Osteosarcoma | 1 | 2020 | 951 | 0.110 |
Why?
|
| Receptors, Formyl Peptide | 1 | 2013 | 12 | 0.110 |
Why?
|
| Phosphates | 1 | 2014 | 178 | 0.110 |
Why?
|
| Lymphocyte Count | 3 | 2013 | 485 | 0.110 |
Why?
|
| Leuprolide | 1 | 2013 | 66 | 0.110 |
Why?
|
| Mastocytoma | 1 | 2012 | 6 | 0.110 |
Why?
|
| Cell Movement | 5 | 2012 | 2468 | 0.110 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2013 | 84 | 0.100 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 663 | 0.100 |
Why?
|
| Leukocytes | 1 | 2014 | 420 | 0.100 |
Why?
|
| Adenoviridae | 1 | 2017 | 1490 | 0.100 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2017 | 866 | 0.100 |
Why?
|
| New York City | 1 | 2012 | 76 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2012 | 246 | 0.100 |
Why?
|
| Peyer's Patches | 1 | 2011 | 30 | 0.100 |
Why?
|
| Indoles | 3 | 2013 | 1029 | 0.100 |
Why?
|
| Oximes | 1 | 2013 | 191 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2014 | 1623 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 9 | 2020 | 5759 | 0.090 |
Why?
|
| beta-Defensins | 1 | 2011 | 31 | 0.090 |
Why?
|
| Drug Administration Routes | 1 | 2011 | 61 | 0.090 |
Why?
|
| Multiple Myeloma | 1 | 2023 | 2336 | 0.090 |
Why?
|
| Gene Expression Profiling | 3 | 2017 | 5146 | 0.090 |
Why?
|
| STAT1 Transcription Factor | 1 | 2011 | 162 | 0.090 |
Why?
|
| Nitric Oxide | 1 | 2014 | 657 | 0.090 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2010 | 58 | 0.090 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2015 | 1011 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2017 | 800 | 0.090 |
Why?
|
| Blotting, Western | 4 | 2013 | 3567 | 0.090 |
Why?
|
| Immunity | 1 | 2012 | 352 | 0.080 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2011 | 209 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2017 | 9048 | 0.080 |
Why?
|
| Galactosylceramides | 1 | 2009 | 25 | 0.080 |
Why?
|
| Cytoplasm | 1 | 2011 | 702 | 0.080 |
Why?
|
| Receptors, Interleukin | 1 | 2009 | 97 | 0.080 |
Why?
|
| Luciferases, Firefly | 1 | 2008 | 40 | 0.080 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2009 | 217 | 0.080 |
Why?
|
| Immunocompetence | 1 | 2008 | 72 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 2014 | 1309 | 0.080 |
Why?
|
| HLA Antigens | 1 | 2011 | 593 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2016 | 2157 | 0.080 |
Why?
|
| Thiazoles | 1 | 2012 | 727 | 0.080 |
Why?
|
| Alternative Splicing | 1 | 2011 | 610 | 0.080 |
Why?
|
| Toll-Like Receptor 9 | 3 | 2017 | 81 | 0.080 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 2192 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2020 | 2674 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2020 | 1571 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 1188 | 0.070 |
Why?
|
| Neoplasm Transplantation | 2 | 2009 | 1553 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2021 | 16752 | 0.070 |
Why?
|
| Interleukin-17 | 1 | 2009 | 251 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2010 | 1825 | 0.070 |
Why?
|
| Mice, Inbred NOD | 1 | 2010 | 896 | 0.070 |
Why?
|
| Natural Killer T-Cells | 1 | 2009 | 117 | 0.070 |
Why?
|
| Lung Neoplasms | 8 | 2020 | 12045 | 0.070 |
Why?
|
| Endothelium, Vascular | 2 | 2010 | 863 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 2394 | 0.070 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 1833 | 0.070 |
Why?
|
| Interleukin-23 Subunit p19 | 1 | 2006 | 4 | 0.070 |
Why?
|
| Sulfonamides | 2 | 2013 | 1943 | 0.070 |
Why?
|
| Interleukin-23 | 1 | 2006 | 28 | 0.070 |
Why?
|
| Transduction, Genetic | 3 | 2015 | 493 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2017 | 3081 | 0.060 |
Why?
|
| B7-1 Antigen | 2 | 2012 | 84 | 0.060 |
Why?
|
| Disease Progression | 1 | 2017 | 6881 | 0.060 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2002 | 186 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2007 | 525 | 0.060 |
Why?
|
| Inflammation | 1 | 2014 | 2491 | 0.060 |
Why?
|
| Heterografts | 2 | 2017 | 739 | 0.060 |
Why?
|
| Mice, Nude | 3 | 2018 | 4332 | 0.060 |
Why?
|
| Brain | 1 | 2017 | 4199 | 0.060 |
Why?
|
| Cell Differentiation | 2 | 2012 | 4105 | 0.060 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2020 | 195 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2009 | 589 | 0.060 |
Why?
|
| Immunologic Factors | 2 | 2023 | 669 | 0.060 |
Why?
|
| Radioimmunotherapy | 1 | 2024 | 128 | 0.060 |
Why?
|
| STAT3 Transcription Factor | 1 | 2010 | 1131 | 0.050 |
Why?
|
| Major Histocompatibility Complex | 1 | 2003 | 99 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 1503 | 0.050 |
Why?
|
| Flow Cytometry | 4 | 2015 | 3040 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2015 | 2884 | 0.050 |
Why?
|
| Cell Survival | 3 | 2017 | 3058 | 0.050 |
Why?
|
| Colonic Neoplasms | 4 | 2024 | 1437 | 0.050 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 2001 | 41 | 0.050 |
Why?
|
| Weight Loss | 1 | 2006 | 628 | 0.050 |
Why?
|
| Neoplasm Staging | 4 | 2024 | 14037 | 0.050 |
Why?
|
| Calcineurin Inhibitors | 1 | 2001 | 68 | 0.050 |
Why?
|
| Immunization | 3 | 2015 | 383 | 0.050 |
Why?
|
| Herpesvirus 8, Human | 1 | 2001 | 107 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 2001 | 246 | 0.040 |
Why?
|
| Viral Envelope Proteins | 1 | 2001 | 196 | 0.040 |
Why?
|
| Receptors, OX40 | 2 | 2012 | 51 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2020 | 404 | 0.040 |
Why?
|
| Biomarkers, Tumor | 3 | 2017 | 10731 | 0.040 |
Why?
|
| Monophenol Monooxygenase | 1 | 2000 | 60 | 0.040 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2021 | 103 | 0.040 |
Why?
|
| Pregnancy Proteins | 1 | 2000 | 42 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2023 | 585 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 709 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2008 | 1715 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 3 | 2017 | 3205 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2012 | 3671 | 0.040 |
Why?
|
| Immunophenotyping | 2 | 2019 | 1724 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2024 | 9054 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2001 | 495 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 381 | 0.040 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2000 | 87 | 0.040 |
Why?
|
| Ovalbumin | 2 | 2011 | 388 | 0.040 |
Why?
|
| HLA-A2 Antigen | 1 | 2000 | 172 | 0.040 |
Why?
|
| Virus Activation | 1 | 2001 | 241 | 0.040 |
Why?
|
| Calcium Signaling | 1 | 2001 | 281 | 0.040 |
Why?
|
| Transendothelial and Transepithelial Migration | 1 | 2019 | 16 | 0.040 |
Why?
|
| Male | 11 | 2021 | 128522 | 0.040 |
Why?
|
| DNA, Recombinant | 1 | 1999 | 160 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 7647 | 0.040 |
Why?
|
| Cell Line | 3 | 2012 | 5313 | 0.040 |
Why?
|
| Macrophage-1 Antigen | 1 | 1998 | 51 | 0.040 |
Why?
|
| Prognosis | 4 | 2020 | 22533 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 3582 | 0.040 |
Why?
|
| Gene Expression | 2 | 2017 | 3606 | 0.040 |
Why?
|
| Survival Rate | 2 | 2020 | 12535 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2019 | 157 | 0.040 |
Why?
|
| Glycosylation | 1 | 2019 | 229 | 0.040 |
Why?
|
| Micelles | 1 | 2018 | 39 | 0.040 |
Why?
|
| Mice, Inbred DBA | 2 | 2012 | 117 | 0.040 |
Why?
|
| Simian virus 40 | 1 | 1999 | 240 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2021 | 33860 | 0.040 |
Why?
|
| Receptors, Interleukin-21 | 1 | 2017 | 14 | 0.040 |
Why?
|
| Poxviridae | 1 | 1997 | 8 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 2001 | 316 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2018 | 590 | 0.040 |
Why?
|
| Italy | 1 | 2017 | 190 | 0.040 |
Why?
|
| Amino Acid Sequence | 3 | 2000 | 4532 | 0.040 |
Why?
|
| Neutrophil Infiltration | 1 | 2017 | 105 | 0.040 |
Why?
|
| Systems Biology | 1 | 2017 | 115 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2021 | 6259 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 561 | 0.030 |
Why?
|
| Time Factors | 2 | 2011 | 12979 | 0.030 |
Why?
|
| Neutrophils | 1 | 2021 | 855 | 0.030 |
Why?
|
| Codon | 1 | 2016 | 260 | 0.030 |
Why?
|
| Genes, bcl-2 | 1 | 2016 | 172 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 2000 | 435 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2017 | 410 | 0.030 |
Why?
|
| Ligands | 1 | 1998 | 1007 | 0.030 |
Why?
|
| Vesicular Stomatitis | 1 | 2015 | 7 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 2017 | 335 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2016 | 651 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2017 | 487 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 2344 | 0.030 |
Why?
|
| Whole-Body Irradiation | 1 | 2015 | 323 | 0.030 |
Why?
|
| Morpholines | 1 | 2015 | 296 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2015 | 223 | 0.030 |
Why?
|
| Peptide Library | 1 | 2014 | 148 | 0.030 |
Why?
|
| S100 Proteins | 1 | 2014 | 184 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 2014 | 167 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 31117 | 0.030 |
Why?
|
| Viral Vaccines | 1 | 1996 | 301 | 0.030 |
Why?
|
| Molecular Imaging | 1 | 2015 | 186 | 0.030 |
Why?
|
| Transfection | 3 | 2008 | 3109 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2020 | 9281 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 590 | 0.030 |
Why?
|
| Lymphocytes | 2 | 2008 | 1273 | 0.030 |
Why?
|
| B7-2 Antigen | 1 | 2012 | 53 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2015 | 574 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2010 | 6639 | 0.020 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2013 | 160 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2015 | 800 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 3534 | 0.020 |
Why?
|
| Middle Aged | 5 | 2021 | 90570 | 0.020 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2011 | 18 | 0.020 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2011 | 35 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 4103 | 0.020 |
Why?
|
| Receptors, CCR6 | 1 | 2011 | 24 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 757 | 0.020 |
Why?
|
| Cross-Priming | 1 | 2011 | 40 | 0.020 |
Why?
|
| Spleen | 2 | 2008 | 719 | 0.020 |
Why?
|
| Young Adult | 3 | 2017 | 22255 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2011 | 76 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2011 | 104 | 0.020 |
Why?
|
| Lentivirus | 1 | 2011 | 165 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2013 | 319 | 0.020 |
Why?
|
| Chemokine CXCL1 | 1 | 2010 | 67 | 0.020 |
Why?
|
| Interleukin-15 Receptor alpha Subunit | 1 | 2010 | 9 | 0.020 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2010 | 30 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2017 | 1555 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 1587 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 902 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 1117 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2012 | 485 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2011 | 556 | 0.020 |
Why?
|
| Cyanoacrylates | 1 | 2010 | 38 | 0.020 |
Why?
|
| Aged | 4 | 2021 | 73641 | 0.020 |
Why?
|
| CD27 Ligand | 1 | 2010 | 26 | 0.020 |
Why?
|
| Interleukin-5 | 1 | 2010 | 67 | 0.020 |
Why?
|
| Pyridones | 1 | 2013 | 364 | 0.020 |
Why?
|
| Th17 Cells | 1 | 2011 | 162 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2011 | 285 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2001 | 3435 | 0.020 |
Why?
|
| Antigens, CD | 2 | 2007 | 1420 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2017 | 1216 | 0.020 |
Why?
|
| Luciferases | 1 | 2010 | 454 | 0.020 |
Why?
|
| Adult | 4 | 2021 | 82074 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 3463 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2009 | 87 | 0.020 |
Why?
|
| Epitopes | 1 | 2011 | 699 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1195 | 0.020 |
Why?
|
| Dasatinib | 1 | 2012 | 881 | 0.020 |
Why?
|
| Biopsy | 1 | 2016 | 3490 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 887 | 0.020 |
Why?
|
| Prostatic Neoplasms | 2 | 2002 | 5870 | 0.020 |
Why?
|
| Protein Engineering | 1 | 2008 | 97 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2011 | 908 | 0.020 |
Why?
|
| OX40 Ligand | 1 | 2008 | 23 | 0.020 |
Why?
|
| Tumor Necrosis Factors | 1 | 2008 | 34 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 3429 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2008 | 55 | 0.020 |
Why?
|
| Lymphocyte Depletion | 2 | 2000 | 316 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2008 | 157 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 841 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 965 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 1439 | 0.020 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2007 | 49 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 843 | 0.020 |
Why?
|
| Retroviridae | 1 | 2008 | 372 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2010 | 5053 | 0.020 |
Why?
|
| Immunization, Secondary | 2 | 1998 | 110 | 0.020 |
Why?
|
| Exons | 1 | 2011 | 1388 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2007 | 170 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2008 | 184 | 0.020 |
Why?
|
| MART-1 Antigen | 2 | 1997 | 113 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 9464 | 0.020 |
Why?
|
| Lectins, C-Type | 1 | 2007 | 163 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2012 | 4966 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2007 | 202 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2012 | 1754 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 1580 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2012 | 2413 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2007 | 254 | 0.020 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2011 | 838 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2006 | 104 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 3472 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 690 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2002 | 2986 | 0.020 |
Why?
|
| Transplantation Tolerance | 1 | 2005 | 19 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 10409 | 0.020 |
Why?
|
| Stem Cells | 1 | 2011 | 1213 | 0.010 |
Why?
|
| Algorithms | 1 | 2015 | 3908 | 0.010 |
Why?
|
| Adolescent | 2 | 2017 | 32698 | 0.010 |
Why?
|
| United States | 1 | 2021 | 15834 | 0.010 |
Why?
|
| Pyridines | 1 | 2010 | 1312 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2013 | 6344 | 0.010 |
Why?
|
| Virus Replication | 2 | 1997 | 762 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2007 | 2087 | 0.010 |
Why?
|
| Abatacept | 1 | 2001 | 40 | 0.010 |
Why?
|
| Ionomycin | 1 | 2001 | 35 | 0.010 |
Why?
|
| Maleimides | 1 | 2001 | 22 | 0.010 |
Why?
|
| Thapsigargin | 1 | 2001 | 43 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2001 | 248 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 10268 | 0.010 |
Why?
|
| Staurosporine | 1 | 2001 | 147 | 0.010 |
Why?
|
| NFATC Transcription Factors | 1 | 2001 | 96 | 0.010 |
Why?
|
| Mast-Cell Sarcoma | 1 | 2000 | 5 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2017 | 17083 | 0.010 |
Why?
|
| Capsid | 1 | 2001 | 177 | 0.010 |
Why?
|
| Calcineurin | 1 | 2001 | 128 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2001 | 697 | 0.010 |
Why?
|
| Salmonella typhimurium | 1 | 2000 | 72 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2000 | 97 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2001 | 293 | 0.010 |
Why?
|
| Models, Immunological | 1 | 2000 | 79 | 0.010 |
Why?
|
| Ubiquitins | 1 | 2000 | 92 | 0.010 |
Why?
|
| Sarcoma, Experimental | 1 | 2000 | 68 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2007 | 1715 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2000 | 255 | 0.010 |
Why?
|
| Tacrolimus | 1 | 2001 | 348 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2010 | 2922 | 0.010 |
Why?
|
| Defective Viruses | 1 | 1999 | 38 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2001 | 414 | 0.010 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 1998 | 26 | 0.010 |
Why?
|
| Pentosyltransferases | 1 | 1998 | 26 | 0.010 |
Why?
|
| Lac Operon | 1 | 1998 | 133 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2000 | 931 | 0.010 |
Why?
|
| Clone Cells | 1 | 2000 | 589 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2001 | 478 | 0.010 |
Why?
|
| Immunodominant Epitopes | 1 | 1997 | 60 | 0.010 |
Why?
|
| Genetic Code | 1 | 1997 | 48 | 0.010 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1997 | 120 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2001 | 809 | 0.010 |
Why?
|
| Vaccines, Attenuated | 1 | 1997 | 151 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1997 | 413 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2000 | 1592 | 0.010 |
Why?
|
| Cell Communication | 1 | 1998 | 509 | 0.010 |
Why?
|
| Child | 1 | 2017 | 30572 | 0.010 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 1996 | 109 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2001 | 1420 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1998 | 1683 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1998 | 880 | 0.010 |
Why?
|
| Simian Immunodeficiency Virus | 1 | 1996 | 134 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1997 | 1072 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1997 | 1406 | 0.010 |
Why?
|
| Risk Factors | 1 | 2011 | 17867 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2001 | 4905 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2001 | 3328 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1998 | 2360 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1998 | 1286 | 0.010 |
Why?
|
| Influenza Vaccines | 1 | 1996 | 496 | 0.010 |
Why?
|
| Base Sequence | 1 | 1997 | 5406 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2001 | 4993 | 0.000 |
Why?
|
| Transcription Factors | 1 | 2001 | 5416 | 0.000 |
Why?
|
| Adenocarcinoma | 1 | 1997 | 7920 | 0.000 |
Why?
|